Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data62
The role of patent analysis in target selection49
FAK inhibitors in cancer, a patent review – an update on progress38
Update on mGlu4 modulator patents: 2017 to present36
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)32
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)31
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities31
Caspase inhibitors: a review on recently patented compounds (2016–2023)30
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)27
An updated patent review of AKT inhibitors (2020 – present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)23
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present23
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
A patent review of MAPK inhibitors (2018 – present)22
Inhibition of GTPase KRAS G12D : a review of patent literature21
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review21
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)20
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Antiprotozoal drugs: challenges and opportunities20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202318
An update on PDGFR inhibitors: a patent review (2020 - present)18
A patent review of LPAR1 antagonists (2010 – present)18
An updated patent review on PD-1/PD-L1 antagonists (2022-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
A patent review of IDH1 inhibitors (2018-present)17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 202517
Small-molecule RNA ligands: a patent review (2018–2024)17
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Antimalarial drugs: what’s new in the patents?15
An updated patent review of MALT1 inhibitors (2021–present)15
A patent and literature review of CDK12 inhibitors15
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs14
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes14
Biofilm and bacterial membrane vesicles: recent advances14
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Are patents important indicators of innovation for Chagas disease treatment?13
Sirtuin modulators: a review of patents from 2020 to 202413
Biomedical applications of prokaryotic carbonic anhydrases: an update13
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
An updated patent review of EZH2 inhibitors (2024–present)13
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
An updated patent review of TRPA1 antagonists (2020 – present)12
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)12
The patent review of the biological activity of tropane containing compounds12
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience12
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity11
5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)11
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)11
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)11
A patent review of BRD4 inhibitors (2020–present)11
Correction11
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)11
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress11
0.24553418159485